Prostate cancer in 2011: Redefining the therapeutic landscape for CRPC

Nature Reviews Urology

Volumn 9, Issue 2, 2012, Pages 63-64

  Pezaro, Carmel ^a   Attard, Gerhardt ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; CABAZITAXEL; DENOSUMAB; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM; SIPULEUCEL T; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; JAW OSTEONECROSIS; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84857034381     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.235     Document Type: Review

References (10)

1. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
2. Attard, G. & de Bono, J. S. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin. Cancer Res. 17, 3867-3675 (2011).
3. Scher, H. I. et al. Evaluation of circulating tumor cell enumeration as an efficacy response biomarker of overall survival in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate plus low-dose prednisone post docetaxel [abstract]. J. Clin. Oncol. 29, LBA4517 (2011).
4. Mulholland, D. J. et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19, 792-804 (2011).
5. Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011).
6. Wang, Y. et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30, 4327-4338 (2011).
7. Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011).
8. de Bono, J., Sandhu, S. & Attard, G. Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell 19, 573-574 (2011).
9. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011).
10. Parker, C. et al. Overall survival benefit of radium-223 chloride (Alpharadan) in the treatment of patients with symptomatic bone metastasis in castration-resistant prostate cancer: a phase III randomised trial (ALSYMPCA) [abstract LBA1]. Presented at the 16th ECCO-36th ESMO Annual Congress.